LI
LFCR icon

Leap Investments’s Lifecore Biomedical LFCR Stock Holding History

Leap Investments’s Portfolio LFCR Stock Details LFCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-10,786
Closed -$117K – 504
2019
Q3 		$117K Buy
+10,786
New +$117K 0.06% 354

Other funds holding LFCR

WC
Wynnefield Capital New York $148M AUM 32.71% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
NIMC
NWQ Investment Management Company Los Angeles, California $2.22B AUM 6.84% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WC
Walthausen & Co Malta, New York $120M AUM 2.66% 1-Year Est. Return
LPAM
Legion Partners Asset Management Los Angeles, California $138M AUM 53.69% 1-Year Est. Return
HA
Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return
ICOM
Investment Counselors of Maryland Baltimore, Maryland $4.37B AUM 76.25% 1-Year Est. Return

Leap Investments's LFCR Position: Q4 2019 in Review

Leap Investments sold out of Lifecore Biomedical (LFCR) in Q4 2019, closing a stake of 10,786 shares — an estimated $117K sold.

Leap Investments first reported a position in LFCR in Q3 2019 and held it in 1 quarter. The position peaked at $117K in Q3 2019. 93 funds tracked by Wall St. Rank hold LFCR as of Q4 2019.

  • Leap Investments reported no remaining Lifecore Biomedical position as of Q4 2019 after selling out during the quarter.
  • Leap Investments sold 10,786 Lifecore Biomedical shares in Q4 2019, an estimated $117K.
  • Leap Investments first reported a position in Lifecore Biomedical in Q3 2019 and held it in 1 quarter.
  • Leap Investments's Lifecore Biomedical position peaked at $117K in Q3 2019.
  • 93 funds tracked by Wall St. Rank held Lifecore Biomedical as of Q4 2019.

Based on Leap Investments's 13F filing for Q4 2019, filed 14 Feb 2020.